Growth hormone releaser attenuates beta-amyloid (1 - 42)-induced memory impairment in mice

J Pharmacol Sci. 2005 Sep;99(1):117-20. doi: 10.1254/jphs.sc0050105. Epub 2005 Sep 1.

Abstract

Accumulating evidence indicates that growth hormone (GH) might be effective at preventing the development of Alzheimer's disease. However, exogenous GH treatment has exhibited side effects for clinical application; thus supplementation with amino acids to promote the release of GH could be a possible alternative treatment. In this study, mice that were fed with a diet of GH-releasing supplements had significantly attenuated memory impairments and hippocampal changes in the acetylcholinesterase activity and acetylcholine level induced by amyloid beta protein (Abeta) (1 - 42). Our results suggest that the use of GH-releasing supplement exerts beneficial effects on the memory impairment induced by Abeta (1 - 42).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / metabolism
  • Acetylcholinesterase / metabolism
  • Aging / physiology*
  • Amino Acids / administration & dosage
  • Amino Acids / pharmacology*
  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Animals
  • Brain / drug effects
  • Brain / enzymology
  • Brain Chemistry
  • Growth Hormone / blood*
  • Growth Hormone / pharmacology
  • Male
  • Memory / drug effects*
  • Memory Disorders / chemically induced
  • Memory Disorders / prevention & control*
  • Mice
  • Mice, Inbred C57BL
  • Peptide Fragments / antagonists & inhibitors*
  • Time Factors

Substances

  • Amino Acids
  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • Growth Hormone
  • Acetylcholinesterase
  • Acetylcholine